Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022

Harvard Apparatus Regenerative Technology, Inc.

2021-Q3 EPS reported -$0.22

Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.
Nine-month 2021 net loss of $2.1M ($0.22 per share) vs $3.8M ($0.45 per share) in prior comparable period.
Cash on-hand $2.0M as of Sep 30, 2021, up $1.5M from prior year.
Proceeds of $2.6M from private placements of 1.3M shares and warrants in first nine months of 2021.
Expects current cash to fund operating expenses and capex into Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.